NASDAQ:FENC

Fennec Pharmaceuticals - FENC Stock Forecast, Price & News

$9.76

+0.01 (+0.10%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $9.63
▼
$10.06
50-Day Range: $7.18
▼
$9.76
52-Week Range: $3.82
▼
$10.06

Volume: 177,608 shs
Average Volume: 74,102 shs
Market Capitalization: $256.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.83

Fennec Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 52.0% Upside
$14.83 Price Target
Short Interest: Healthy
2.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.03
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.85) to ($0.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

721st out of 1,043 stocks

Biological Products, Except Diagnostic Industry

117th out of 172 stocks

3.5

Analyst's Opinion

Consensus Rating
Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.83, Fennec Pharmaceuticals has a forecasted upside of 52.0% from its current price of $9.76.
Amount of Analyst Coverage
Fennec Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.86% of the float of Fennec Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Fennec Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fennec Pharmaceuticals has recently increased by 17.39%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Fennec Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fennec Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FENC.

2.2

News and Social Media Coverage

News Sentiment
Fennec Pharmaceuticals has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fennec Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.38% of the stock of Fennec Pharmaceuticals is held by insiders.
Percentage Held by Institutions
43.29% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Fennec Pharmaceuticals are expected to grow in the coming year, from ($0.85) to ($0.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fennec Pharmaceuticals is -11.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fennec Pharmaceuticals is -11.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fennec Pharmaceuticals has a P/B Ratio of 88.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Stock News Headlines

November 26, 2022 | americanbankingnews.com

Analysts Issue Forecasts for Fennec Pharmaceuticals Inc's FY2022 Earnings (NASDAQ:FENC)

November 24, 2022 | markets.businessinsider.com

Expert Ratings for Fennec Pharmaceuticals

November 23, 2022 | americanbankingnews.com

Cantor Fitzgerald Upgrades Fennec Pharmaceuticals (NASDAQ:FENC) to Overweight

November 22, 2022 | markets.businessinsider.com

Where Fennec Pharmaceuticals Stands With Analysts

November 22, 2022 | markets.businessinsider.com

4 Analysts Have This to Say About Fennec Pharmaceuticals

November 22, 2022 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals

September 26, 2022 | finance.yahoo.com

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

September 21, 2022 | finance.yahoo.com

After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss

September 21, 2022 | nasdaq.com

Fennec's Pedmark To Reduce Risk Of Ototoxicity Associated With Cisplatin Scores FDA Nod

September 21, 2022 | finance.yahoo.com

U.S. FDA approves Fennec's hearing loss therapy

September 21, 2022 | finance.yahoo.com

Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

September 19, 2022 | markets.businessinsider.com

Will Fennec's Pedmark Cross FDA Finish Line This Time?

August 23, 2022 | benzinga.com

Fennec Pharmaceuticals (NASDAQ:FENC), Analyst Ratings, Price Targets, Predictions

August 1, 2022 | finance.yahoo.com

RTP drugmaker secures up to $45M despite regulatory speed bumps

May 12, 2022 | finance.yahoo.com

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

May 6, 2022 | finance.yahoo.com

Inflation crushes market caps of Triangle's biggest public companies – except these ones

May 3, 2022 | finance.yahoo.com

Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?

April 27, 2022 | seekingalpha.com

Fennec refiling gets FDA review for Pedmark to prevent chemotherapy-induced hearing loss in children

April 27, 2022 | finance.yahoo.com

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

April 5, 2022 | baystreet.ca

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TLS, FENC and ASTR

March 28, 2022 | benzinga.com

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FENC, CRNC and CABA

March 25, 2022 | bizjournals.com

After two rejections and no revenue, Fennec again seeks FDA approval

March 25, 2022 | finance.yahoo.com

Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference

March 24, 2022 | nasdaq.com

Fennec Resubmits Pedmark NDA To FDA

March 24, 2022 | marketwatch.com

Fennec Pharmaceuticals Files Again for FDA OK of Pedmark >FENC

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Company Calendar

Last Earnings: 11/11/2022
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FENC
CUSIP: N/A
CIK: 1211583
Web: www.fennecpharma.com
Phone: 919-636-4530
Fax: 919-890-0490
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.83
High Stock Price Forecast: $19.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +52.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -214.78%
Return on Assets: -97.25%

Debt

Debt-to-Equity Ratio: 8.81
Current Ratio: 10.30
Quick Ratio: 10.30

Sales & Book Value

Annual Sales: $170,000.00
Price / Sales: 1,506.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.11 per share
Price / Book: 88.73

Miscellaneous

Outstanding Shares: 26,238,000
Free Float: 23,777,000
Market Cap: $256.08 million
Optionable: Optionable
Beta: N/A

Key Executives

Mr. Rostislav Raykov (Age 42)
Pres, CEO & Director

Mr. Robert C. Andrade (Age 43)
Chief Financial Officer

Mr. Mark Gowland
Controller

Mr. Lei Fang
Pres of Pharstat Inc

Ms. Anne McKay (Age 64)
Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings or view top-rated stocks.
What is Fennec Pharmaceuticals' stock price forecast for 2023?: 6 brokerages have issued 1-year price targets for Fennec Pharmaceuticals' stock. Their FENC share price forecasts range from $11.00 to $19.00. On average, they anticipate the company's stock price to reach $14.83 in the next year. This suggests a possible upside of 52.0% from the stock's current price.
View analysts price targets for FENC or view top-rated stocks among Wall Street analysts.
How have FENC shares performed in 2022?: Fennec Pharmaceuticals' stock was trading at $4.40 on January 1st, 2022. Since then, FENC shares have increased by 121.8% and is now trading at $9.76.
View the best growth stocks for 2022 here.
When is Fennec Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our FENC earnings forecast.
How were Fennec Pharmaceuticals' earnings last quarter?: Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its earnings results on Friday, November, 11th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.14.

What other stocks do shareholders of Fennec Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).
What is Fennec Pharmaceuticals' stock symbol?: Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."
Who are Fennec Pharmaceuticals' major shareholders?: Fennec Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (1.47%), Tamarack Advisers LP (0.67%), Group One Trading L.P. (0.00%), BlackRock Inc. (0.19%), Hartford Financial Management Inc. (0.15%) and Jane Street Group LLC (0.06%).
View institutional ownership trends.
How do I buy shares of Fennec Pharmaceuticals?: Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fennec Pharmaceuticals' stock price today?: One share of FENC stock can currently be purchased for approximately $9.76.
How much money does Fennec Pharmaceuticals make?: Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $256.08 million and generates $170,000.00 in revenue each year. The company earns $-17,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.
How can I contact Fennec Pharmaceuticals?: Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page (NASDAQ:FENC) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fennec Pharmaceuticals - FENC Stock Forecast, Price & News

Fennec Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

FENC Stock News Headlines

FENC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

FENC Stock - Frequently Asked Questions

Overall MarketRank^™